Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib’s efficacy

A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

Being a patient can be a full-time job. This ICU nurse wants to make it easier

Michael Anne Kyle had just begun her Ph.D. in health policy and management at Harvard Business School when her friends started complaining about the health

October 25, 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | Psychedelic Invest

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

January 17, 2025

New study defines clinical phenotype of Post-infectious ME/CFS, highlighting unique biomarker insights

The pathophysiological mechanisms of PI myalgic encephalitis/chronic fatigue syndrome (ME/CFS).

February 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.